Description
Cytokeratin 18-M65 (CK18-M65), also known as CK18M65, is a marker used in the assessment of cell death and liver injury, particularly in the context of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and liver fibrosis. CK18-M65 is a specific fragment of cytokeratin 18, a protein found in epithelial cells, including hepatocytes.
Background:
Cytokeratin 18 is a structural protein found in epithelial tissues, including the liver. During cell death processes such as apoptosis and necrosis, cytokeratin 18 is cleaved by caspases, leading to the release of various fragments into the bloodstream. CK18-M65 is a specific fragment released during cell death and is considered a marker of hepatocyte apoptosis and liver injury.
Pathways and Relevance:
CK18-M65 has emerged as a valuable biomarker for assessing liver injury and disease progression in conditions such as NAFLD, NASH, alcoholic liver disease, and viral hepatitis. Elevated levels of CK18-M65 in serum are indicative of increased hepatocyte apoptosis and are associated with the severity of liver damage, inflammation, and fibrosis. Monitoring CK18-M65 levels can provide insights into disease prognosis, treatment response, and risk stratification for liver-related complications.
Research on CK18-M65 is ongoing, with studies focusing on its utility in diagnosing and monitoring liver diseases, predicting disease progression, and evaluating the efficacy of therapeutic interventions. Additionally, researchers are exploring the potential of CK18-M65 as a non-invasive biomarker for assessing liver fibrosis and guiding treatment decisions in clinical practice. As the understanding of liver disease pathophysiology continues to evolve, CK18-M65 remains a promising marker for improving the management of patients with liver disorders.
In summary, CK18-M65 serves as a valuable tool in the assessment of liver injury and disease progression, offering insights into hepatocyte apoptosis and liver pathophysiology. Its relevance in clinical practice underscores its importance as a biomarker for improving the diagnosis, monitoring, and management of liver diseases.
Validated against seven points for a “GOLD RING” Standard Quality ELISA – the benchmark sign for Krishgen Quality. The The GENLISA ELISA kits are used for assessing the specific biomarker in samples analytes which may be human serum, plasma, biological fluids and cell culture supernatant. The kit uses indirect sandwich assay with double antibodies – capture and detection to ensure a high degree of sensitivity and specificity in the estimation of Cytokeratin 18-M65 (CK18-M65 / CK18M65);
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: kbiinfo@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!